BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Bipolar Disorder readouts · AssetMemo
X-WR-CALDESC:Upcoming phase 1/2 and later readouts in Bipolar Disorder\, fr
 om ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07185815-803@assetmemo.bio
DTSTAMP:20261121T002711Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Cariprazine (Vraylar): Phase 1/2 readout est. (NCT07185815)
DESCRIPTION:Cariprazine (Vraylar)\, phase 1/2\, Major Depressive Disorder.\
 nStudy: Pharmacokinetics\, Safety\, Tolerability and Efficacy of a Subcuta
 neous Long-Acting Injection of Cariprazine (Cariprazine Depot) in Subjects
  Eligible for Treatment With Oral Cariprazine\nEstimated primary completio
 n: 31 December 2026. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 cariprazine-vraylar#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07185815
URL:https://assetmemo.bio/drug/cariprazine-vraylar#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04777357-803@assetmemo.bio
DTSTAMP:20261121T002711Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Cariprazine (Vraylar): Phase 3 readout est. (NCT04777357)
DESCRIPTION:Cariprazine (Vraylar)\, phase 3\, Bipolar Disorder.\nStudy: A S
 tudy to Assess Change in Disease Activity and Adverse Events (AEs) With Ca
 riprazine in the Treatment of Depressive Episodes in Pediatric Participant
 s Participants (10 to 17 Years of Age) With Bipolar I Disorder.\nEstimated
  primary completion: March 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/cariprazine-vraylar#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT04777357
URL:https://assetmemo.bio/drug/cariprazine-vraylar#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07140913-712@assetmemo.bio
DTSTAMP:20261121T002711Z
DTSTART;VALUE=DATE:20270628
DTEND;VALUE=DATE:20270629
SUMMARY:Cobenfy (Xanomeline/trospium chloride): Phase 3 readout est. (NCT07
 140913)
DESCRIPTION:Cobenfy (Xanomeline/trospium chloride)\, phase 3\, Bipolar Diso
 rder.\nStudy: A Study to Evaluate the Efficacy and Safety of Adjunctive Ka
 rXT for the Treatment of Mania\, With or Without Mixed Features\, in Parti
 cipants With Bipolar-I Disorder Taking Lithium\, Valproate\, or Lamotrigin
 e\nEstimated primary completion: 28 June 2027. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/xanomeline-trospium-chloride#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07140913
URL:https://assetmemo.bio/drug/xanomeline-trospium-chloride#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07540338-10983@assetmemo.bio
DTSTAMP:20261121T002711Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Lithium salicylate/L-proline (AL001): Phase 1/2 readout est. (NCT07
 540338)
DESCRIPTION:Lithium salicylate/L-proline (AL001)\, phase 1/2\, Bipolar Diso
 rder.\nStudy: A Study to Investigate Lithium Brain/Plasma Pharmacokinetics
  and Safety of an AL001 Oral Capsule Compared to a Marketed Immediate-rele
 ase Lithium Carbonate Capsule in Subjects With Bipolar I Disorder\nEstimat
 ed primary completion: July 2027. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/lithium-salicylate-l-proline-al001#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07540338
URL:https://assetmemo.bio/drug/lithium-salicylate-l-proline-al001#upcoming-
 events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06656416-804@assetmemo.bio
DTSTAMP:20261121T002711Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:ALTO-100: Phase 2 readout est. (NCT06656416)
DESCRIPTION:ALTO-100\, phase 2\, Bipolar Disorder.\nStudy: ALTO-100 in Bipo
 lar Disorder With Depression (BD-D)\nEstimated primary completion: Septemb
 er 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/alto-100#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0665641
 6
URL:https://assetmemo.bio/drug/alto-100#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04987229-9210@assetmemo.bio
DTSTAMP:20261121T002711Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Olanzapine/samidorphan (Lybalvi): Phase 3 readout est. (NCT04987229
 )
DESCRIPTION:Olanzapine/samidorphan (Lybalvi)\, phase 3\, Schizophrenia.\nSt
 udy: Long-term Safety Extension Study of OLZ/SAM in Pediatric Subjects\nEs
 timated primary completion: September 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/olanzapine-samidorphan-lybalvi#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT04987229
URL:https://assetmemo.bio/drug/olanzapine-samidorphan-lybalvi#upcoming-even
 ts
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07286175-822@assetmemo.bio
DTSTAMP:20261121T002711Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Brenipatide: Phase 2 readout est. (NCT07286175)
DESCRIPTION:Brenipatide\, phase 2\, Bipolar Disorder.\nStudy: A Study of Br
 enipatide in Adult Participants With Bipolar Disorder (RENEW-Bipolar-1)\nE
 stimated primary completion: November 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/brenipatide#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07286175
URL:https://assetmemo.bio/drug/brenipatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06696755-837@assetmemo.bio
DTSTAMP:20261121T002711Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Icalcaprant: Phase 2 readout est. (NCT06696755)
DESCRIPTION:Icalcaprant\, phase 2\, Bipolar Disorder.\nStudy: A Study to As
 sess Adverse Events and Change in Disease Activity of Oral Icalcaprant in 
 Adult Participants With Bipolar I or II Disorder\nEstimated primary comple
 tion: November 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 icalcaprant#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT06696755
URL:https://assetmemo.bio/drug/icalcaprant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06929273-712@assetmemo.bio
DTSTAMP:20261121T002711Z
DTSTART;VALUE=DATE:20280613
DTEND;VALUE=DATE:20280614
SUMMARY:Cobenfy (Xanomeline/trospium chloride): Phase 3 readout est. (NCT06
 929273)
DESCRIPTION:Cobenfy (Xanomeline/trospium chloride)\, phase 3\, Bipolar Diso
 rder.\nStudy: A Study to Assess the Long-term Safety of KarXT for the Trea
 tment of Manic Episodes in Bipolar-I Disorder (BALSAM-3)\nEstimated primar
 y completion: 13 June 2028. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/xanomeline-trospium-chloride#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT06929273
URL:https://assetmemo.bio/drug/xanomeline-trospium-chloride#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06929273-4820@assetmemo.bio
DTSTAMP:20261121T002711Z
DTSTART;VALUE=DATE:20280613
DTEND;VALUE=DATE:20280614
SUMMARY:Lamotrigine: Phase 3 readout est. (NCT06929273)
DESCRIPTION:Lamotrigine\, phase 3\, Bipolar Disorder.\nStudy: A Study to As
 sess the Long-term Safety of KarXT for the Treatment of Manic Episodes in 
 Bipolar-I Disorder (BALSAM-3)\nEstimated primary completion: 13 June 2028.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/lamotrigine#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT06929273
URL:https://assetmemo.bio/drug/lamotrigine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
